AARTIDRUGS vs WANBURY: Stock Comparison

Aarti Drugs Limited vs Wanbury Ltd

Live data: 22 July 2026, 3:07 PM IST • Source: NSE and company filings

Aarti Drugs Limited is the larger company by market capitalisation. Aarti Drugs Limited shows a higher dividend yield, faster revenue growth and lower leverage, while Wanbury Ltd shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarti Drugs Limited and Wanbury Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AARTIDRUGS is more favourable on 4 of 13 scored metrics and WANBURY on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
AARTIDRUGS is the larger company
₹3,769 Cr vs ₹1,143 Cr
P/E Ratio
WANBURY has a lower P/E
0x vs 20.04x
P/B Ratio
WANBURY has a lower P/B
0x vs 2.52x
EPS
AARTIDRUGS has higher earnings per share
₹21.81 vs ₹13.1
Dividend Yield
AARTIDRUGS has a higher dividend yield
0.48% vs 0%
Revenue Growth (TTM YoY)
AARTIDRUGS has faster revenue growth
6.4% vs -19.2%
EPS Growth (TTM YoY)
WANBURY has faster EPS growth
0% vs -12%
Qtr Sales Growth
WANBURY has stronger quarterly sales growth
24.5% vs 6.43%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSWANBURY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSWANBURY
Live Price₹411.15₹327.15
Day Change-3.69%-3.32%
Volume2.96 L4.38 L
52-Week High₹551.75₹358.85
52-Week Low₹318.95₹161.5
Distance from 52W High-25.48%-8.83%

Valuation

MetricAARTIDRUGSWANBURY
Market Cap₹3,769 Cr₹1,143 Cr
P/E Ratio20.04x0x
P/B Ratio2.52x0x
EPS₹21.81₹13.1
Book Value₹169.79₹18.1
Dividend Yield0.48%0%

Growth

MetricAARTIDRUGSWANBURY
Revenue Growth (TTM YoY)6.4%-19.2%
EPS Growth (TTM YoY)-12%0%
Qtr Sales Growth6.43%24.5%
Qtr Profit Growth-12.2%1,197%

Profitability & Leverage

MetricAARTIDRUGSWANBURY
ROE13.4%76.5%
ROCE11.9%36.6%
Net Margin7.6%10.17%
Operating Margin12%14%
Debt to Equity0.37x3.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAARTIDRUGSWANBURY
Promoter Holding55.03%34.36%
FII Holding1.58% 0.57 pp0.89% 0.3 pp
DII Holding10.22% 0.1 pp0.06% 0.06 pp
Public Holding33.18% 0.48 pp56.03% 0.36 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarti Drugs Limited and Wanbury Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.